Research Topics
Species | P GreenwaldSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cancer chemopreventionPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 2040, Bethesda, Maryland 20892-7309, USA
BMJ 324:714-8. 2002
Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasiaJames R Marshall
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...- A favorable view: progress in cancer prevention and screeningPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7309, USA
Recent Results Cancer Res 174:3-17. 2007..If these biomarkers can be validated, they might help to reduce cancer mortality... - Lifestyle and medical approaches to cancer preventionPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 2040, Bethesda, MD 20892 7309, USA
Recent Results Cancer Res 166:1-15. 2005.... - Clinical trials in cancer prevention: current results and perspectives for the futurePeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Nutr 134:3507S-3512S. 2004.... - The future of cancer preventionPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Room 2040, 31 Center Dr, MSC 2580, Bethesda, MD 20892 7309, USA
Semin Oncol Nurs 21:296-8. 2005..To hypothesize on the future of cancer prevention based on past and current progress of the field, as well as possible assimilation of knowledge in other fields that may be applied to cancer prevention... - Preface. The applications of bioinformatics in cancer detectionPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Betheda, MD 20892-7309, USA
Ann N Y Acad Sci 1020:ix-x. 2004 - An evidence-based approach to cancer prevention clinical trialsPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Suite 2040, Bethesda, MD 20892 7309, USA
Eur J Cancer Prev 11:S43-7. 2002..Development of valid surrogate end point biomarkers for clinical disease that can be modulated by interventions is essential to accelerate progress in cancer prevention clinical trials... - Clinical trials of vitamin and mineral supplements for cancer preventionPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7309, USA
Am J Clin Nutr 85:314S-317S. 2007.... - Cancer prevention clinical trialsPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7309, USA
J Clin Oncol 20:14S-22S. 2002..In addition, two lifestyle factors that have potential to influence cancer risk-obesity and functionally enhanced foods-are discussed in the context of their link between clinical and public health-related research... - From carcinogenesis to clinical interventions for cancer preventionP Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Suite 2040, Bethesda, MD 20892 7309, USA
Toxicology 166:37-45. 2001..The development of valid intermediate biomarkers that can serve as surrogate endpoints for clinical disease is urgently needed to accelerate advances in clinical trials for cancer prevention... - Diet and cancer preventionP Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Building 31, Room 10A52, 31 Center Drive, MSC 2580, Bethesda, MD 20892 2580, USA
Eur J Cancer 37:948-65. 2001..Such basic research is fundamental to cancer prevention strategies that incorporate effective dietary interventions for target populations... - Creating a new paradigm in nutrition research within the National Cancer InstituteP Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
J Nutr 130:3103-5. 2000.... - Molecular targets for nutrients involved with cancer preventionJ A Milner
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
Nutr Cancer 41:1-16. 2001..Undeniably, embracing new genomic technologies offers exciting opportunities for advances in the broad area of nutrition, especially those related to cancer prevention... - Cancer risk factors for selecting cohorts for large-scale chemoprevention trialsP Greenwald
Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Cell Biochem Suppl 25:29-36. 1996..The validation of biomarkers as surrogate endpoints for cancer incidence in high-risk cohorts will allow more agents to be evaluated in shorter studies that use fewer subjects to achieve the desired statistical power... - Cancer chemoprevention: progress and promiseG J Kelloff
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Eur J Cancer 35:2031-8. 1999..The large number of chemoprevention research programmes now ongoing ensures that the promise of chemoprevention will continue to be realised in the next decade... - Overview of U.S. National Cancer Institute (USNCI) chemoprevention researchK A Johnson
Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Maryland 29892
Acta Oncol 33:5-11. 1994..Resources required for large-scale trials compel greater attention to efficient trial design, concept development and review, priority setting, management, budgeting, and collaboration... 
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenomaI U Ali
Division for Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Bethesda, MD 20892, USA
Br J Cancer 93:953-9. 2005..Our analysis underscores the significance of the overall allelic architecture of Cox-2 as an important determinant for risk assessment...- Cancer risk and diet in IndiaR Sinha
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892 7273, USA
J Postgrad Med 49:222-8. 2003..From a public health perspective, there is an increasing need to develop cancer prevention programs responsive to the unique diets and cultural practices of the people of India... - Plasma proteomic profiling: search for lung cancer diagnostic and early detection markersIqbal Unnisa Ali
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Oncol Rep 15:1367-72. 2006..Validation of these biomarkers would have significant implications for the early detection of lung cancer and better management of high-risk patients... - Nutritional interventions in cancer preventionPhilip R Taylor
National Cancer Institute, 6116 Executive Blvd, Rm 705, Bethesda, MD 20892 8314, USA
J Clin Oncol 23:333-45. 2005.... - Nutrition and physical activity and chronic disease prevention: research strategies and recommendationsRoss L Prentice
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3 A410, Seattle, WA 98109 1024, USA
J Natl Cancer Inst 96:1276-87. 2004.... - Serum proteomic profiles suggest celecoxib-modulated targets and response predictorsZhen Xiao
Laboratory of Proteomics and Analytical Technologies and Advanced Biomedical Computing Center, SAIC-Frederick Inc, National Cancer Institute at Frederick, Frederick, Maryland, USA
Cancer Res 64:2904-9. 2004..In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose... - The antioxidant conundrum in cancerHarold E Seifried
Division of Cancer Prevention, National Cancer Institute NIH, 6130 Executive Boulevard, Suite 3160, Bethesda, MD 20852, USA
Cancer Res 63:4295-8. 2003..Overall, current knowledge makes it premature to generalize and make specific recommendations about antioxidant usage for those at high risk for cancer or undergoing treatment... - Micronutrients in cancer chemopreventionPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7309, USA
Cancer Metastasis Rev 21:217-30. 2002..Research priorities include investigation of possible molecular targets for micronutrients and whether genetic and epigenetic events dictate direction and magnitude of the response... - Beta-carotene and lung cancer: a lesson for future chemoprevention investigations?Peter Greenwald
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Natl Cancer Inst 95:E1. 2003 - Toward improved implementation of evidence-based clinical algorithms: clinical practice guidelines, clinical decision rules, and clinical pathwaysGary M Gaddis
St Luke s Hospital of Kansas City and University of Missouri Kansas City School of Medicine, Kansas City, MO, USA
Acad Emerg Med 14:1015-22. 2007.... - A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraineBenjamin W Friedman
Department of Emergency Medicine, Albert Einstein College of Medicine, Bronx, NY 10467, USA
Ann Emerg Med 52:399-406. 2008..We compare prochlorperazine 10 mg intravenously versus metoclopramide 20 mg intravenously for the emergency department (ED) treatment of acute migraine...